Li Li, Secretary of the Party Leadership Group and Director of the National Medical Products Administration (NMPA), stated in an interview that pharmaceutical regulation work is closely related to people's livelihoods. During the 15th Five-Year Plan period, pharmaceutical regulation will consistently regard enhancing the public's sense of gain, happiness, and security as its fundamental starting point and ultimate goal. The aim is to ensure that the achievements of reform and development benefit the entire population more extensively and fairly, and to continuously meet the people's aspirations for a better life and their needs for health protection.
The NMPA will make full use of accelerated pathways, such as breakthrough therapy designation, conditional approval, priority review and approval, and special approval procedures. This will expedite the review and approval of urgently needed overseas new drugs, rare disease drugs, and pediatric medicines, shortening the distance from laboratory to bedside and allowing innovative achievements to benefit public welfare more quickly.
The administration will adhere to the principles of "standards not lowered, procedures not reduced," steadily expanding the scope of the consistency evaluation for the quality and efficacy of generic drugs, ensuring that high-quality, affordable medicines benefit more patients. Furthermore, it will actively promote pilot reforms for age-appropriate and accessibility enhancements to drug instructions, encouraging the provision of accessible versions of drug labeling to truly translate regulatory effectiveness into public satisfaction.

https://finance.eastmoney.com/a/202512103587950511.html